Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00551408|
Recruitment Status : Completed
First Posted : October 31, 2007
Last Update Posted : October 16, 2018
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.
Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.
|Condition or disease|
|Pulmonary Idiopathic Arterial Hypertension|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||October 2016|
20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00551408
|Unidad de Investigacion Clinica en Medicina SC.|
|Monterrey, Nuevo Leon, Mexico, 64020|
|Principal Investigator:||Carlos J Sanchez Diaz, MD.||Unidad de Investigacion Clinica en Medicina SC.|